Research & Development

[Kathleen Sheffer]

Results published by the European Respiratory Journal in February 2018 reported Opsumit (Macitentan) failed to achieve the goals of a Phase 2 clinical trial over a 12-week period. Researchers concluded that patients treated with Opsumit were “quantitatively more likely to experience significant fluid retention versus placebo” and that the drug had no significant impact on the patients’ heart function. (Read more).

The FDA approved Opsumit for PH patients in 2013. Are you on this therapy? Did you participate in the trial? What symptoms do you experience?

[Author]

Posts